POM-V Prescription Required

Dugnixon 50 mg/ml Solution for Injection for Cattle, Pigs and Horses

Active ingredient: Flunixin

Form

Injection

Species

Cattle Horses Pigs

Manufacturer

Global Vet Health S.L.

VMD MA No.

36167/4005

What it's used for

Alleviation of acute inflammation and pain associated with musculoskeletal disorders. AN: 02405/2024 & 02631/2024 Reduction of post-operative pain associat...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Flunixin

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Dugnixon 50 mg/ml Solution for Injection for Cattle, Pigs and Horses — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

Alleviation of acute inflammation and pain associated with musculoskeletal
disorders.
AN: 02405/2024 & 02631/2024
Reduction of post-operative pain associated with dehorning in calves of less than 9
weeks.
Horses
Alleviation of acute inflammation and pain associated with musculoskeletal
disorders.
Alleviation of visceral pain associated with colic.
Adjunctive therapy of endotoxemia due to or as a result of post-surgical or medical
conditions or diseases that result in impaired blood circulation in the gastrointestinal
tract.
Reduction of pyrexia.
Pigs
Adjunctive therapy in the treatment of swine respiratory disease.
Adjunctive treatment of postpartum dysgalactia (Mastitis-Metritis-Agalactia)
syndrome in sows.
Alleviation of acute inflammation and pain associated with musculoskeletal
disorders.
Reduction of post-operative pain following castration and tail docking in sucking
piglets.

intravenous route. Repeat as necessary at 24-hour intervals for up to 3 consecutive
days.
For intramuscular use, if dose volumes exceed 8 ml, it should be divided and
injected into two or three sites. In case that more than three site are necessary, the
intravenous route should be used.
Reduction of post-operative pain associated with dehorning in calves of less than 9
weeks
A single intravenous administration of 2.2 mg of flunixin per kg bodyweight (2 mL per
45 kg), 15-20 minutes before the procedure.
Horses
Alleviation of acute inflammation and pain associated with musculoskeletal disorders
and reduction of pyrexia
1.1 mg flunixin/kg bodyweight (1 ml per 45 kg) once daily for up to 5 days according
to clinical response.
Alleviation of visceral pain associated with colic
1.1 mg flunixin/kg bodyweight (1 ml per 45 kg). Repeat once or twice if colic recurs.
Adjunctive therapy of endotoxemia due to or as a result of post-surgical or medical
conditions or diseases that result in impaired blood circulation in the gastrointestinal
tract
AN: 02405/2024 & 02631/2024
0.25 mg flunixin/kg bodyweight every 6-8 hours or 1.1 mg flunixin/kg bodyweight
once daily for up to 5 consecutive days.
Pigs
Adjunctive therapy in the treatment of swine respiratory disease, adjunctive
treatment of postpartum dysgalactia (Mastitis-Metritis-Agalactia) syndrome in sows,
alleviation of acute inflammation and pain associated with musculoskeletal disorders
2.2 mg flunixin/kg bodyweight (2 ml per 45 kg) once daily for up to 3 consecutive
days.
The injection volume should be limited to a maximum of 4 ml per injection site.
Reduction of post-operative pain following castration and tail docking in sucking
piglets
A single administration of 2.2 mg of flunixin per kg bodyweight (0.2 mL per 4.5 kg),
15-30 minutes before the procedure.
Particular care should be taken with regard to the accuracy of dosing including the
use of an appropriate dosing device and careful estimation of body weight.
To ensure a correct dosage, body weight should be determined as accurately as
possible.
In order to prevent excessive broaching of the rubber stopper, the 50 ml and 100 ml
vials should not be broached more than 25 times and the 250 ml vial not more than
50 times.

Do not use in animals suffering from cardiac, hepatic or renal diseases or where
there is the possibility of gastro intestinal ulceration or bleeding.
Do not use in cases of hypersensitivity to the active substance or to any of the
excipients.
Do not use if haematopoiesis or haemostasis is impaired.
Do not use in cases of colic caused by ileus and associated with dehydration.

Cattle
Uncommon
(1 to 10 animals / 1 000
animals treated):
Injection site reaction (such as injection site irritation

and injection site swelling).
Rare
(1 to 10 animals / 10 000
animals treated):
Liver disorder;
Renal disorder (Nephropathy, Papillary necrosis)
.
Very rare
(<1 animal / 10 000
animals treated, including
Anaphylaxis (e.g. Anaphylactic shock,
Hyperventilation, Convulsion, Collapse, Death)
;
Ataxia
;
AN: 02405/2024 & 02631/2024
isolated reports):Blood and lymphatic system disorder
, Haemorrhage;
Digestive tract disorder (gastrointestinal irritation,
gastrointestinal ulceration, digestive tract
haemorrhage, nausea, blood in faeces, diarrhoea)
;
Delay of parturition
, stillbirth
, retained placenta
;
Appetite loss.
Particularly in hypovolaemic and hypotensive animals.
After intravenous administration. At the onset of the first symptoms, administration
should be stopped immediately and, if necessary, anti-shock treatment should be
started.
Blood count abnormalities.
By a tocolytic effect induced by inhibition of the synthesis of prostaglandins,
responsible for the initiation of parturition.
If the product is used in the period following parturition.
Horses
Uncommon
(1 to 10 animals / 1 000
animals treated):
Injection site reaction (such as injection site irritation

and injection site swelling).
Rare
(1 to 10 animals / 10 000
animals treated):
Liver disorder;
Renal disorder (Nephropathy, Papillary necrosis)
.
Very rare
(<1 animal / 10 000
animals treated, including
isolated reports):
Anaphylaxis (e.g. Anaphylactic shock,
Hyperventilation, Convulsion, Collapse, Death)
;
Ataxia
;
Blood and lymphatic system disorder
, Haemorrhage;
Digestive tract disorder (gastrointestinal irritation,
gastrointestinal ulceration, digestive tract
haemorrhage, nausea, blood in faeces, diarrhoea)
;
Delay of parturition
, stillbirth
, retained placenta
;
Excitation
;
Muscle weakness
;
Appetite loss.
Particularly in hypovolaemic and hypotensive animals.
After intravenous administration. At the onset of the first symptoms, administration
should be stopped immediately and, if necessary, anti-shock treatment should be
started.
Blood count abnormalities.
By a tocolytic effect induced by inhibition of the synthesis of prostaglandins,
responsible for the initiation of parturition.
If the product is used in the period following parturition.
May occur through accidental intra-arterial injection.
Pigs
Uncommon
(1 to 10 animals / 1 000
animals treated):
Injection site reaction (such as injection site skin
discolouration, injection site pain, injection site
irritation

and injection site swelling)
.
Rare
(1 to 10 animals / 10 000
animals treated):
Liver disorder;
Renal disorder (Nephropathy, Papillary necrosis)
.
Very rare
(<1 animal / 10 000
animals treated, including
Anaphylaxis (e.g. Anaphylactic shock,
Hyperventilation, Convulsion, Collapse, Death)
;
Ataxia
;
AN: 02405/2024 & 02631/2024
isolated reports):Blood and lymphatic system disorder
, Haemorrhage;
Digestive tract disorder (gastrointestinal irritation,
gastrointestinal ulceration, digestive tract
haemorrhage, vomiting, nausea, blood in faeces,
diarrhoea)
;
Delay of parturition
, stillbirth
, retained placenta
;
Appetite loss.
Resolves spontaneously within 14 days.
Particularly in hypovolaemic and hypotensive animals.
After intravenous administration. At the onset of the first symptoms, administration
should be stopped immediately and, if necessary, anti-shock treatment should be
started.
Blood count abnormalities.
By a tocolytic effect induced by inhibition of the synthesis of prostaglandins,
responsible for the initiation of parturition.
If the product is used in the period following parturition.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian,
to either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.

None.

Special precautions for safe use in the target species:
Inject slowly as life threating symptoms of shock can occur due to the content of
propylene glycol.
NSAIDs are known to have the potential to delay parturition through a tocolytic effect
by inhibiting prostaglandins that are important in signalling the initiation of parturition.
The use of the veterinary medicinal product in the immediate post-partum period
may interfere with uterine involution and expulsion of foetal membranes resulting in
retained placentae.
The veterinary medicinal product should have a temperature close to body
temperature. Stop injection immediately after first symptoms of shock and start
shock treatment if necessary.
Use of NSAIDs in hypovolemic animals or animals with shock should be subject to a
benefit-risk evaluation performed by the responsible veterinarian due to the risk of
renal toxicity.
AN: 02405/2024 & 02631/2024
Use in very young (cattle, horses: less than 6 weeks old) as well as in old animals
may involve additional risks. If such treatment cannot be avoided, careful clinical
observation is indicated. The underlying cause of pain, inflammation or colic should
be determined and, when appropriate, antibiotic or re-hydration therapy should be
given concurrently.
NSAIDs can cause phagocytosis inhibition and, therefore, in the treatment of
inflammatory states associated with bacterial infections, appropriate concurrent
antimicrobial therapy should be established.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
This veterinary medicinal product may cause hypersensitivity (allergy) reactions.
People with known hypersensitivity to non-steroidal anti-inflammatory drugs such as
flunixin and /or propylene glycol should avoid contact with the veterinary medicinal
product. In case of hypersensitivity reactions seek medical advice and show the
package leaflet or the label to the physician.
This veterinary medicinal product may cause skin and eye irritation. Avoid contact
with skin and eyes. Wash hands after use. In case of accidental skin contact, wash
affected area immediately with plenty of water.
In case of accidental eye contact, rinse eyes immediately with plenty of water. If skin
and /or eye irritation persists, seek medical advice immediately and show the
package leaflet or the label to the physician.
Accidental self-injection may cause pain and inflammation. In case of accidental self-
injection, seek medical advice immediately and show the package leaflet or the label
to the physician.
Laboratory studies in rats with flunixin have shown evidence of foetotoxic effects.
Pregnant women should use the veterinary medicinal product with serious caution to
avoid accidental self-injection.
Special precautions for the protection of the environment:
Flunixin is toxic to avian scavengers. Do not administer to animals susceptible to
enter wild fauna food chain. In case of death or sacrifice of treated animals, ensure
that they are not made available to wild fauna.

Do not administer other non-steroidal anti-inflammatory drugs (NSAIDs) concurrently
or within 24 hours of each other. Do not administer corticosteroids concurrently.
AN: 02405/2024 & 02631/2024
Concurrent use of other NSAIDs or corticosteroids may increase the risk of gastro-
intestinal ulceration.
Some NSAIDs may be highly bound to plasma proteins and compete with other
highly bound drugs which can lead to toxic effects.
Flunixin may decrease the effect of some antihypertensive drugs by inhibiting
prostaglandin synthesis, such as diuretics, ACE inhibitors (angiotensin converting
enzyme inhibitors), and beta blockers.
Concomitant administration of potentially nephrotoxic drugs (e.g., aminoglycoside
antibiotics) should be avoided.

Store below 25 °C
Keep the vial in the outer carton in order to protect from light.

Cattle:
Meat and offal: 4 days (intravenous use)
31 days (intramuscular use)
Milk: 24 hours (intravenous use)
36 hours (intramuscular use)
Pigs
Meat and offal: 24 days (intramuscular use)
Horses:
Meat and offal: 5 days (intravenous use)
Milk: Not authorised for use in animals producing milk for human consumption

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.